Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00210314
Status:
COMPLETED
Last Update Posted:
2015-03-30
First Post:
2005-09-13
Brief Title:
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
Sponsor:
International Extranodal Lymphoma Study Group IELSG
Organization:
International Extranodal Lymphoma Study Group IELSG
Study Overview
Official Title:
Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate Alone or Associated With High-dose Cytarabine Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of the study is to establish in a prospective randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate alone or combined with high dose cytarabine in patients with primary central nervous system lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None